ABOUT ONCOLOGYSTAT
Our Editorial Board and Editorial Team
Press Releases and Press Coverage
OUR MISSION
OncologySTAT's mission is to promote state-of-the-art cancer care by providing oncology professionals with instant online access to the highest-quality news, expert opinion, and clinical information, including free full-text articles from over 100 Elsevier cancer-related journals.
OUR CONTENT
OncologySTAT offers an unprecedented array of professional cancer research, information, and education resources in a single online destination, with a breadth and depth of content that is unrivaled. All site content is organized by 29 cancer types, enabling oncologists to instantly and easily access the latest news, scientific updates, and expert opinion pertaining to their specialty.
Key features of the site include:
- Free access to recent full-text articles from over 100 Elsevier cancer-related journals, including The Lancet Oncology, The Breast, Lung Cancer, The American Journal of Medicine, Cancer Letters, etc
- Journal Scans, concise summaries of the most important articles from the leading cancer journals (eg, JCO, JNCI, CA, Blood, JAMA, NEJM), selected on a weekly basis by our expert editors and writers
- 29 Cancer-type spotlights, allowing all content for a specific cancer to be easily accessed from a single page
- Customized online CME programs
- Premier medical and pharmaceutical news provided by Elsevier Global Medical News and FDC Reports
- Expert commentary, interviews, and blogs
- Conference Coverage, including premeeting expert abstract recommendations, news coverage, videos, and expert analyses of the top oncology conferences
- What Your Patients Are Reading, synopses of cancer-related stories reported in the lay media and on the Internet
- Chemotherapy regimens from The Elsevier Guide to Oncology Drugs & Regimens (updated in 2008)
- Professional drug monograph and interactions database powered by Gold Standard
- RSS feeds for News, Journal Scans, and What Your Patients Are Reading
- Integrated Medline search
- Selected sections of textbook content from Abeloff’s Clinical Oncology (3rd edition)
- Weekly InfoBLAST, News, and Journal Scan e-newsletters
- Video network of interviews with key opinion leaders
- Downloadable patient handouts
OUR ADVISORY BOARD
OncologySTAT is guided by a world-renowned Advisory Board that represents community practitioners and academic specialists with cross-disciplinary expertise. The Advisory Board includes 2 past presidents of ASCO.
OUR EDITORIAL BOARD AND EDITORIAL TEAM
The OncologySTAT editorial team is led by an esteemed Editorial Board—Editor-in-Chief Lee S. Schwartzberg, MD, FACP, and Associate Editors, Isabel Cunningham, MD, and Axel Grothey, MD. These physician editors apply their diverse experiences in clinical oncology practice, academia, and research to ensure that all of OncologySTAT’s editorial content fulfills the site’s primary mission. They also contribute monthly commentary on newsworthy and often controversial issues relevant to oncology practice. The editorial team consists of physicians, oncology fellows, and experienced medical writers and editors.
Editor-in-Chief: Lee S. Schwartzberg, MD, FACP
Associate Editor: Isabel Cunningham, MD
Associate Editor: Axel Grothey, MD
Managing Editor: Ellen Powers
Web Content Manager: Megan Doremus
Medical Writer: Lauren Scott-Zoeller
Medical Editors: Barbara Bekiesz
Contributors: Patrick W. Cobb, MD, FACP,
Alissa Marr, MD, Alberto Mizrachi, MD, Ted Okon, David Portnoy, MD, Ryan Ramaekers, MD
HOW WE GET PAID
OncologySTAT is commercially supported by online advertising, sponsorship, and educational grants. Individual access to OncologySTAT is free. Premium content is available to any user who registers with the site.
While OncologySTAT is a commercially-sponsored product, it maintains the highest level of academic rigor, objectivity, and fair balance associated with all Elsevier products. No editorial content on the site is influenced in any way by commercial sponsors or content contributors.
EDUCATIONAL PROGRAMS
OncologySTAT provides a targeted online delivery channel for accredited and nonaccredited eCME/CME programs to cancer care and research professionals around the world. OncologySTAT can facilitate the delivery of live interactive educational programs, as well as preexisting educational content that can be hosted and delivered on-demand for a specified time period. For more information regarding OncologySTAT professional programs, please contact Neethu Joseph at n.joseph@elsevier.com.
STRATEGIC ALLIANCES
OncologySTAT invites inclusion of high-quality basic, clinical, and translational research articles, news, conference coverage, original content, and educational programs from recognized publishers, societies, and research organizations. We also welcome reciprocal linking arrangements with reputable cancer information and research websites.
For more information regarding OncologySTAT content integration and partnership opportunities, please contact Mark Placito at m.placito@elsevier.com.
ABOUT ELSEVIER
Elsevier is a world-leading publisher of scientific, technical, and medical information products and services. Working in partnership with the global science and health communities, Elsevier’s 7000 employees in over 70 offices worldwide publish more than 2000 journals and 1900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect, MD Consult, Scopus, bibliographic databases, and online reference works.
Elsevier is a global business headquartered in Amsterdam, The Netherlands, and has offices worldwide. Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK, and ENL (New York Stock Exchange).
Last Revised: September 16, 2009
Sign up for our newsletters
Too busy to follow cancer's top stories? Sign-up for one or more of our leading newsletters -- delivered weekly to your inbox.
